Clinical trial NCT02107196: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Official title: A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Irritable Bowel Syndrome With Diarrhea
Keywords: Irritable Bowel Syndrome
Colon, irritable
Bowel disease
Diarrhea
Lead sponsor: Menarini Group
Sponsor class: INDUSTRY
First posted: 2014-04-08
Enrollment: 535
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period.

Detailed description: The study evaluates the efficacy and safety of ibodutant 10 mg, given once daily for 12 weeks in comparison with placebo in female IBS-D patients. Randomisation to ibodutant and placebo will be 1:1. Efficacy is evaluated in terms of weekly response for abdominal pain intensity and stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment.

The clinical phase of the study comprises up to 2 weeks of screening for patient's eligibility, a 2-week run-in period (treatment-free) for IBS severity assessment, a 12-week double-blind treatment period, a 4-week randomised withdrawal (RW) period and a 2-week safety follow-up, resulting in a maximum 22-week overall duration of the study for each patient.

Patients report their IBS-related symptoms daily in a telephone-based electronic diary from run-in until end of treatment.

Eligibility criteria: Inclusion Criteria:

At screening:

* Female patients aged 18 years or older.
* Clinical diagnosis of IBS-D according to the following symptoms-based criteria as per Rome III modular questionnaire criteria:

  1. Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.
  2. Symptom-onset at least 6 months prior to diagnosis.
  3. Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
  4. Additional criterion: more than 3 bowel movements per day at least 25% of the time in the last 3 months.
* For patients older than 50 years OR patients with a positive family history of colorectal cancer: normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years.
* For patients aged 65 years or older: absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months.
* For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate \<1% per year throughout the entire study period.
* Physical examination without clinically relevant abnormalities during screening.
* No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings.
* Mentally competent, able to give written informed consent, and compliant to undergo all visits and procedures.
* Unrestricted access to a touch-tone telephone.
* Willingness to refrain from using loperamide within 3 days prior to run-in visit and during the run-in period.

Additional criteria at randomisation:

* During both weeks of the run-in period:

  1. A weekly average of worst abdominal pain in the past 24 hours with a score of ≥3.0 on a 0 to 10 point scale.
  2. At least one bowel movement on each day.
  3. A weekly average of at least 3 bowel movements per day.
  4. At least one stool with a consistency of Type 6 or Type 7 according to the Bristol Stool Scale (BSS) on at least 2 days per week.
  5. Less than 2 bowel movements with a consistency of Type 1 or Type 2 according to the BSS per week.
* Adequate compliance with the e-diary recording procedure defined as at least 11 of 14 days (≥75%) of the nominal daily data entry.

Exclusion Criteria:

* Male gender.
* Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS.
* Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study.
* History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis.
* History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months.
* History of gluten enteropathy or lactose intolerance.
* Current or previous diagnosis of neoplasia.
* History of endometriosis.
* History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months.
* History of human immunodeficiency virus infection.
* History of major cardiovascular events in the previous 6 months.
* Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function.
* Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments.
* Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia.
* Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.
* Use of prohibited concurrent medication within the previous month such as antibiotics, antimuscarinic drugs, drugs enhancing GI motility and analgesics.
* Pregnancy or breastfeeding.
* Inability to understand or collaborate throughout the study.
* Participation in other clinical studies in the previous 4 weeks or concurrent enrollment in a clinical study.
* Any condition that would compromise the well-being of the patient.

Primary outcomes:
measure: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).
timeFrame: 12 weeks
Secondary outcomes:
measure: Weekly Response for Abdominal Pain Intensity Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).
timeFrame: 12 weeks
measure: Weekly Response for Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).
timeFrame: 12 weeks
measure: Weekly Response for Relief of Overall IBS Signs and Symptoms Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).
timeFrame: 12 weeks
measure: Evaluation of Rebound Effects
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Huntsville
country: United States
state: Alabama
city: Sherwood
country: United States
state: Arizona
city: Little Rock
country: United States
state: Arkansas
city: Artesia
country: United States
state: California
city: Chula Vista
country: United States
state: California
city: Encino
country: United States
state: California
city: Mission Hills
country: United States
state: California
city: Sacramento
country: United States
state: California
city: San Diego
country: United States
state: California
city: Upland
country: United States
state: California
city: Littleton
country: United States
state: Colorado
city: Bristol
country: United States
state: Connecticut
city: Boynton Beach
country: United States
state: Florida
city: Brandon
country: United States
state: Florida
city: Brooksville
country: United States
state: Florida
city: Coral Gables
country: United States
state: Florida
city: Gainesville
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Jupiter
country: United States
state: Florida
city: Miami Lakes
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Addison
country: United States
state: Illinois
city: Chicago
country: United States
state: Illinois
city: Augusta
country: United States
state: Kansas
city: Newton
country: United States
state: Kansas
city: Wichita
country: United States
state: Kansas
city: Lexington
country: United States
state: Kentucky
city: Madisonville
country: United States
state: Kentucky
city: Owensboro
country: United States
state: Kentucky
city: Crowley
country: United States
state: Louisiana
city: Baltimore
country: United States
state: Maryland
city: Ann Arbor
country: United States
state: Michigan
city: Chesterfield
country: United States
state: Michigan
city: Saginaw
country: United States
state: Michigan
city: Troy
country: United States
state: Michigan
city: Las Vegas
country: United States
state: Nevada
city: Hartsdale
country: United States
state: New York
city: Fayetteville
country: United States
state: North Carolina
city: Greensboro
country: United States
state: North Carolina
city: Fargo
country: United States
state: North Dakota
city: Akron
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Cleveland
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Dayton
country: United States
state: Ohio
city: Reading
country: United States
state: Pennsylvania
city: Greer
country: United States
state: South Carolina
city: Simpsonville
country: United States
state: South Carolina
city: Chattanooga
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: Nashville
country: United States
state: Tennessee
city: Smyrna
country: United States
state: Tennessee
city: Beaumont
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Hurst
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Ste. Channelview
country: United States
state: Texas
city: West Jordan
country: United States
state: Utah
city: Morgantown
country: United States
state: West Virginia
city: Haskovo
country: Bulgaria
city: Plovdiv
country: Bulgaria
city: Ruse
country: Bulgaria
city: Sofia
country: Bulgaria
city: Sofia
country: Bulgaria
city: Veliko Tarnovo
country: Bulgaria
city: Karlovy Vary
country: Czech Republic
city: Prague
country: Czech Republic
city: Prague
country: Czech Republic
city: Usti nad Labem
country: Czech Republic
city: Usti nad Orlici
country: Czech Republic
city: Bobigny
country: France
state: Ile-de-France
city: Bordeaux
country: France
city: Nantes Cedex
country: France
city: NICE Cedex
country: France
city: Rouen
country: France
city: Stuttgart
country: Germany
state: Baden-Wuerttemberg
city: Berlin
country: Germany
city: Berlin
country: Germany
city: Essen
country: Germany
city: Hamburg
country: Germany
city: Hamburg
country: Germany
city: Bari
country: Italy
city: Bari
country: Italy
city: Bologna
country: Italy
city: Florence
country: Italy
city: Pavia
country: Italy
city: Rome
country: Italy
city: Bydgoszcz
country: Poland
city: Czestochowa
country: Poland
city: Krakow
country: Poland
city: Lublin
country: Poland
city: Wroclaw
country: Poland
city: Targu Mures
country: Romania
state: Jud. Mures
city: Tirgu Mures
country: Romania
state: Mures
city: Timisoara
country: Romania
state: Timis
city: Timisoara
country: Romania
state: Timis
city: Brasov
country: Romania
city: Brasov
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Kaluga
country: Russian Federation
city: Moscow
country: Russian Federation
city: Saint-Petersburg
country: Russian Federation
city: Smolensk
country: Russian Federation
city: St. Petersburg
country: Russian Federation
city: St.Petersburg
country: Russian Federation
city: Yaroslavl
country: Russian Federation
city: Badalona
country: Spain
state: Barcelona
city: Mataro
country: Spain
state: Barcelona
city: Sabadell
country: Spain
state: Barcelona
city: Barcelona
country: Spain
city: Barcelona
country: Spain
city: Madrid
country: Spain
city: Sevilla
country: Spain
city: Penzance
country: United Kingdom
state: Cornwall
city: Chesterfield
country: United Kingdom
state: Derbyshire
city: Inverness
country: United Kingdom
state: Scotland
city: Doncaster
country: United Kingdom
state: South Yorkshire
city: Leicestershire
country: United Kingdom
city: Manchester
country: United Kingdom
city: Plymouth, Devon
country: United Kingdom
Study officials:
affiliation: Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
name: Jan F Tack, Professor
role: STUDY_CHAIR
affiliation: Digestive Health and Nutrition Clinic. University of California, Los Angeles, CA, USA
name: Lin Chang, Professor
role: STUDY_CHAIR
References: